2021;9:e1113
however, the safety profile of semaglutide in each SUSTAIN and PIONEER trial individually has previously been reported.16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33 The limitations of our analysis include the low number of CV events and the short trial durations of SUSTAIN 6 (planned exposure 104 weeks and median followup 2.1 years) and PIONEER 6 (median followup 1.3 years) compared with other CVOTs
10.1080/10520295.2023.2287452 9 HuZ.WuL.LvY.GeC.LuoX.ZhanS.et al (2025)
Cost and Accessibility The impact of GLP-1 receptor agonists on healthcare budgets and patient accessibility cannot be overlooked: Higher Cost: These medications often come at a higher price point compared to other diabetic treatments, which can affect their accessibility for some patients